AstraZeneca (AZN) has signed a deal with CanoSino Biologics (CASBF) to develop messenger RNA vaccines, Hannah Kuchler and William Langley of The Financial Times reports. The companies have not disclosed the value of the deal.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AZN:
- AstraZeneca price target raised to 12,700 GBp from 12,600 GBp at Morgan Stanley
- 5 Healthcare Stocks to Buy Now, According to Analysts – August 2023
- Sanofi says CDC panel unanimously recommends use of Beyfortus for infants
- AstraZeneca and Sanofi RSV drug wins support of CDC panel, Bloomberg says
- Zentalis appoints Freeman as Chief Strategy Officer